Relation between paradoxical decrease in high-density lipoprotein cholesterol levels after statin therapy and adverse...

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Statin therapy typically increases high-density lipoprotein cholesterol (HDL-C).
• A subset of patients paradoxically experiences decreased HDL-C levels despite statin treatment.
• Acute myocardial infarction (AMI) survivors are a critical population for cardiovascular risk assessment.

Purpose of the Study:

• To investigate the clinical significance of paradoxical HDL-C decrease post-statin therapy in AMI patients.
• To identify predictors of adverse cardiovascular events in this population.
• To evaluate the association between HDL-C changes and long-term cardiovascular outcomes.

Main Methods:

• Retrospective analysis of 724 patients with AMI initiating statin therapy.
• Patients categorized into HDL-C increasing and decreasing groups based on 6-9 month follow-up.
• Adverse cardiovascular events (death, MI, stroke) tracked and compared between groups.
• Multivariate analysis performed to identify independent predictors of adverse events.

Main Results:

• 620 patients showed increased HDL-C, while 104 showed decreased HDL-C.
• Both groups achieved target low-density lipoprotein cholesterol levels (<100 mg/dl).
• The decreased HDL-C group experienced significantly more adverse cardiovascular events (15.4% vs 7.1%, p=0.01).
• Decreased HDL-C, longer onset-to-balloon time, and multivessel disease were independent predictors of adverse events.

Conclusions:

• A paradoxical decrease in serum HDL-C after statin initiation may serve as an independent predictor of long-term adverse cardiovascular events in AMI patients.
• This finding suggests that HDL-C response to statins warrants further investigation in cardiovascular risk stratification.
• Monitoring HDL-C changes could offer additional prognostic information beyond LDL-C levels.